Navigation Links
Data published in PNAS show antibodies can be made 10 times more toxic to cancer cells

Engineering the "Fc" region of monoclonal antibodies (mAbs) increases their toxicity to cancer cells, potentially improving the utility of targeted cancer therapies, according to research conducted at Xencor, which will be published in the March 14 print issue of the Proceedings of the National Academy of Sciences (PNAS).

Monoclonal antibodies have important advantages over chemotherapy and small molecule drug treatments for cancer, such as their specificity in targeting tumor cells and low toxicity. There are currently eight approved anticancer antibody products on the market today and many more are in development. Unfortunately, many marketed treatments lack the desired potency against tumor cells, providing only incremental improvements in therapeutic success, and many development-stage antibodies fail in clinical trials due to lack of demonstrated efficacy.

Scientists at Xencor, a biotherapeutics company developing protein and antibody therapeutics, said the changes it made to the antibody Fc regions increased antibody effector functions such as activation of immune cells for tumor lysis, called Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), by more than two orders of magnitude. Studies conducted in in vivo models demonstrated that these antibodies were greater than ten times more toxic to target cells. The enhanced antibodies also were able to kill tumor cells that are typically "invisible" to other antibodies because they express low levels of target antigen.

"While antibodies such as Genentech's Rituxan are well known for their role in the treatment of cancer, many other promising antibodies are sub-optimal for use as therapeutics. They just aren't powerful enough," said Bassil Dahiyat, Ph.D., President and CEO of Xencor. "The work we published in PNAS shows that specific changes to the Fc regions of antibodies have the potential to greatly improve the effectiveness of next-generation antibody therapeutics, and may mean that many more antibodies can be used in the treatment of cancer than ever before."

Xencor's Fc variants were engineered using the company's XmAbTM technology, which couples computational design algorithms with high-throughput screening to rationally design the antibody constant region. The Fc portion of the constant region of the antibody has been shown in previous studies to be responsible for mediating antibody-dependent cell-mediated cytotoxicity and has been the target of Xencor's XmAb technology. Xencor has leveraged its XmAb technology to develop therapeutic antibodies, for which it plans to begin clinical testing next year.

"We've already applied the XmAb technology used in this research to generate a suite of patented Fc antibody variants that have optimized antibody-Fc receptor affinity, which translate into increased effector functions and improved cell cytotoxicity. These can be used to enhance the potency of nearly any antibody under development today," Dahiyat added.


'"/>

Source:Porter Novelli, Life Sciences


Related biology news :

1. Comprehensive biodefense text published
2. First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology
3. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
4. Combating anthrax: Results of study published this month as researchers look for a better vaccine
5. Genomic comparison of lactic acid bacteria published
6. The first tree genome is published: Poplar holds promise as renewable bioenergy resource
7. Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned
8. Horse antibodies against the bird flu virus H5N1 are effective as treatment in mice
9. Mice studies illustrate potential of chimp/human antibodies to protect against smallpox
10. GlycoFi announces the first production of antibodies with human glycosylation in yeast
11. Report calls for improved monoclonal antibodies against solid tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... ... 2017 , ... Bacterial biofilms, surface adherent communities of bacteria that are encased ... food poisoning and catheter infections to gum disease and the rejection of medical implants. ... dollars per year, there is currently a paucity of means for preventing their formation ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... ... today that it is exhibiting in booth B2 at the Association for ... May 22-25. , In addition to demonstrating its Cancer Diagnostic Cockpit and ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph ... at the Prince Of Wales Private Hospital. The procedure was performed on a ... patient failed conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic disc ...
(Date:5/18/2017)... ... May 17, 2017 , ... Cognition Corporation ... has just released version 9.0 of the Cognition Cockpit platform. , “Our whole ... says David Cronin, CEO of Cognition. “We’re thrilled to finally be able to ...
Breaking Biology Technology: